Daily Cardiology Research Analysis
Three impactful cardiology papers emerged today: multi-omics Mendelian randomization pinpointed distinct, non-overlapping drug targets for HFrEF vs HFpEF; the first randomized comparison of IVL, rotational atherectomy, and excimer laser showed IVL noninferior to RA for stent expansion in calcified lesions; and a meta-analysis of RCTs supports oral anticoagulation alone (vs adding antiplatelet) for AF with stable CAD, reducing major bleeding without increasing ischemic events.
Summary
Three impactful cardiology papers emerged today: multi-omics Mendelian randomization pinpointed distinct, non-overlapping drug targets for HFrEF vs HFpEF; the first randomized comparison of IVL, rotational atherectomy, and excimer laser showed IVL noninferior to RA for stent expansion in calcified lesions; and a meta-analysis of RCTs supports oral anticoagulation alone (vs adding antiplatelet) for AF with stable CAD, reducing major bleeding without increasing ischemic events.
Research Themes
- Multi-omics drug target discovery in heart failure subtypes
- Device strategy for calcified coronary lesions (IVL vs RA vs ELCA)
- Antithrombotic optimization in AF with stable CAD
Selected Articles
1. Large-scale multi-omics identifies drug targets for heart failure with reduced and preserved ejection fraction.
Using Mendelian randomization across >420,000 participants, the authors identified 70 HFrEF and 10 HFpEF causal targets, largely non-overlapping, highlighting the need for subtype-specific therapies. Druggable candidates include IL6R, ADM, and EDNRA for HFrEF and LPA for both subtypes; findings were replicated in >175,000 multi-ancestry participants.
Impact: This work delineates causal, druggable targets for HF subtypes at scale, offering a roadmap for precision therapeutics and re-prioritizing pipelines for HFrEF vs HFpEF.
Clinical Implications: While not immediately practice-changing, the prioritized targets (e.g., IL6R, ADM, EDNRA, LPA) inform trial design and companion biomarker strategies for subtype-specific HF therapies.
Key Findings
- Identified 70 causal targets for HFrEF and 10 for HFpEF; 58 were novel and targets were non-overlapping across subtypes.
- Validated roles of ubiquitin–proteasome system, SUMO pathway, inflammation, and mitochondrial metabolism in HFrEF.
- Druggable candidates include IL6R, ADM, EDNRA (HFrEF) and LPA (both HFrEF and HFpEF); 14 loci reclassified as HFrEF.
Methodological Strengths
- Large-scale Mendelian randomization integrating proteome and transcriptome with replication in >175,000 participants
- Systematic druggability profiling including efficacy, safety, and mechanism of action
Limitations
- Causal inference depends on MR assumptions and potential horizontal pleiotropy
- Translational impact requires interventional trials to confirm therapeutic efficacy
Future Directions: Prospective trials targeting prioritized pathways (e.g., IL6R, ADM/EDNRA signaling, LPA lowering) with subtype-specific enrollment and biomarker-guided stratification.
Heart failure (HF) has limited therapeutic options. In this study, we differentiated the pathophysiological underpinnings of the HF subtypes-HF with reduced ejection fraction (HFrEF) and HF with preserved ejection fraction (HFpEF)-and uncovered subtype-specific therapeutic strategies. We investigated the causal roles of the human proteome and transcriptome using Mendelian randomization on more than 420,000 participants from the Million Veteran Program (27,799 HFrEF and 27,579 HFpEF cases). We created therapeutic target profiles covering efficacy, safety, novelty, druggability and mechanism of action. We replicated findings on more than 175,000 participants of diverse ancestries. We identified 70 HFrEF and 10 HFpEF targets, of which 58 were not previously reported; notably, the HFrEF and HFpEF targets are non-overlapping, suggesting the need for subtype-specific therapies. We classified 14 previously unclassified HF loci as HFrEF. We substantiated the role of ubiquitin-proteasome system, small ubiquitin-related modifier pathway, inflammation and mitochondrial metabolism in HFrEF. Among druggable genes, IL6R, ADM and EDNRA emerged as potential HFrEF targets, and LPA emerged as a potential target for both subtypes.
2. Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: Meta-Analysis of Randomized Trials.
Pooling four RCTs (n=4,092), OAC monotherapy reduced major bleeding (HR 0.59) versus OAC+single antiplatelet without increasing ischemic events or mortality. Results support OAC alone for AF with stable CAD beyond the acute coronary period.
Impact: Resolves a common clinical dilemma by synthesizing randomized evidence favoring OAC monotherapy in AF with stable CAD, likely shaping guidelines and deprescribing practices.
Clinical Implications: In AF with stable CAD beyond the early post-ACS/PCI phase, prefer OAC monotherapy to minimize bleeding; reserve antiplatelet therapy for compelling coronary indications.
Key Findings
- No significant difference in ischemic composite outcomes between OAC monotherapy and OAC+SAPT (HR 0.90).
- Major bleeding significantly lower with OAC monotherapy (3.3% vs 5.7%; HR 0.59).
- Findings consistent across subgroups; exploratory signal suggests greater bleeding reduction in men.
Methodological Strengths
- Meta-analysis restricted to randomized trials with acquisition of unpublished data to refine estimates
- Prespecified subgroup analyses and harmonized outcome definitions
Limitations
- Only four RCTs; some were not powered for individual effectiveness endpoints
- Heterogeneity in OAC agents, SAPT use, and follow-up durations
Future Directions: Head-to-head trials or IPD meta-analyses stratifying by coronary complexity, time from PCI, and bleeding risk to refine patient-level recommendations.
BACKGROUND: The optimal long-term antithrombotic strategy in patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) remains uncertain. Individual randomized controlled trials (RCTs) had variations in their reported results and were not powered for effectiveness outcomes. OBJECTIVES: This study aimed to pool the results of RCTs comparing the effectiveness and safety of oral anticoagulation (OAC) monotherapy vs OAC plus single antiplatelet therapy (SAPT) in patients with AF and stable CAD. METHODS: We systematically searched PubMed, Embase, and ClinicalTrials.gov until September 09, 2024. The primary effectiveness outcome was a composite of myocardial infarction, ischemic stroke, systemic embolism, or death. The primary safety outcome was major bleeding. We obtained unpublished results from principal investigators of the included RCTs, as needed, to calculate pooled HRs and 95% CIs and to perform prespecified subgroup analyses. RESULTS: Among 690 screened records, 4 RCTs with 4,092 randomized patients were included (2 using edoxaban, 1 using rivaroxaban, and 1 using any oral anticoagulant; mean age 73.9 years, 20.1% women). The median follow-up durations ranged from 12 to 30 months (overall estimated weighted mean follow-up of 21.9 months). There were no statistically significant differences between OAC monotherapy vs OAC plus SAPT in the primary effectiveness outcome (7.3% vs 8.2%; HR: 0.90; 95% CI: 0.72-1.12), myocardial infarction (1.0% vs 0.7%; HR: 1.51; 95% CI: 0.75-3.04), ischemic stroke (1.9% vs 2.1%; HR: 0.89; 95% CI: 0.57-1.37), all-cause death (4.2% vs 5.3%; HR: 0.94; 95% CI: 0.49-1.80), or cardiovascular death (2.4% vs 3.0%; HR: 0.79; 95% CI: 0.54-1.15). OAC monotherapy was associated with a lower risk of major bleeding than OAC plus SAPT (3.3% vs 5.7%; HR: 0.59; 95% CI: 0.44-0.79). Subgroup analyses did not show significant interactions for effectiveness but suggested that the magnitude of bleeding reduction may be greater among men (P
3. Rotational Atherectomy, Lithotripsy, or Laser for Calcified Coronary Stenosis: The ROLLER COASTR-EPIC22 Trial.
In the first randomized 3-arm comparison of plaque-modification strategies for calcified lesions, IVL was noninferior to RA for OCT-assessed stent expansion, whereas ELCA did not meet noninferiority. Minimum stent area, procedural success, and complications were similar, with numerically fewer complications in IVL.
Impact: Directly informs device selection in calcified PCI, an area with procedural risk and uncertainty, by providing randomized evidence across three commonly used techniques.
Clinical Implications: For heavily calcified lesions, IVL can be considered an alternative to RA to achieve adequate stent expansion; ELCA may be reserved given failure to meet noninferiority.
Key Findings
- IVL met noninferiority vs RA for OCT-measured stent expansion; ELCA did not meet noninferiority.
- Minimum stent area, procedural success, and complication rates were similar across arms, with numerically fewer complications in IVL.
- Trial enrolled 171 patients with predominantly severe calcification (82.5%) across CCS and ACS presentations.
Methodological Strengths
- Randomized, three-arm, intention-to-treat noninferiority design with OCT core lab endpoint
- Balanced enrollment across CCS and ACS with high prevalence of severe calcification
Limitations
- Modest sample size limits power for clinical endpoints and subgroup analyses
- Noninferiority margin selection and device-specific operator experience may influence outcomes
Future Directions: Larger pragmatic trials powered for clinical outcomes and stratified by calcium severity, vessel size, and combination strategies (e.g., RA+IVL).
BACKGROUND: Coronary calcification negatively affects the safety and effectiveness of percutaneous coronary intervention. There is a lack of randomized comparisons among different plaque modification techniques. OBJECTIVES: The aim of this study was to compare rotational atherectomy (RA), excimer laser coronary angioplasty (ELCA), and intravascular lithotripsy (IVL) for the treatment of patients with calcified coronary stenosis. METHODS: Patients with moderate to severe calcified coronary lesions were randomly assigned to percutaneous coronary intervention with RA, IVL, or ELCA. The primary endpoint was the percentage of stent expansion by optical coherence tomography. An intention-to-treat, noninferiority analysis was conducted. RESULTS: A total of 171 patients (77.2% men [n = 132], mean age 70.9 ± 8.2 years) were enrolled, 57 in each treatment arm. Clinical presentation was chronic coronary syndrome in 64.3% of patients (n = 110) and acute coronary syndrome in 35.7% (n = 61). Severe angiographic calcification was observed in 82.5% of lesions (n = 141). Procedural success rate and final minimum stent area (RA, 5.5 ± 2.1 mm CONCLUSIONS: In the first randomized trial comparing RA, IVL, and ELCA for the treatment of patients with calcified coronary lesions, IVL was noninferior to RA in terms of stent expansion. ELCA did not reach this noninferiority margin compared with RA. No significant differences were observed among the 3 arms regarding minimum stent area, procedural success rate, and complications, which were numerically lower with IVL.